MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
Annals of Hematology · 2024-10 · 103 (10) · 4065-4077
DOI: 10.1007/s00277-024-05908-4 ↗At a glance
Multizentrische Studie in Annals of Hematology, published online on 2024-07-29. Written by Stefanie Jilg and 15 co-authors. Institution: Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de. Major MEDLINE topics: Primary Myelofibrosis. Cited 11 times so far (Crossref); 32 references.
Abstract (original language)
Není k dispozici žádný abstrakt.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de.
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. stefanie.jilg@onkologie-erding.de.
- Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
- Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
- Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
- Department of Hematology and Oncology, University Hospital Erlangen, Friedrich- Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
ORCID profiles: Stefanie Jilg, Madlen Jentzsch, Florian Heidel, Petro E Petrides
Cite
APA
Jilg, S., Schwaab, J., Sockel, K., Crodel, C. C., Brueckl, V., Stegelmann, F., Jentzsch, M., Sasca, D., Moyses, M., Fuhrmann, S., Gundel, D., Caduc, M., Teichmann, L. L., Heidel, F., Al-Ali, H. K., & Petrides, P. E. (2024). MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology, 103(10), 4065-4077. https://doi.org/10.1007/s00277-024-05908-4
Vancouver
Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, et al. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology. 2024;103(10):4065-4077. doi:10.1007/s00277-024-05908-4
BibTeX
@article{Jilg2024,
author = {Jilg, Stefanie and Schwaab, Juliana and Sockel, Katja and Crodel, Carl C and Brueckl, Valeska and Stegelmann, Frank and Jentzsch, Madlen and Sasca, Daniel and Moyses, Margarete and Fuhrmann, Stephan and Gundel, Daniel and Caduc, Madlen and Teichmann, Lino L and Heidel, Florian and Al-Ali, Haifa K and Petrides, Petro E},
title = {MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {10},
pages = {4065--4077},
doi = {10.1007/s00277-024-05908-4}
}
EUVIMED